Biogen Inc. discovers, develops, manufactures, and delivers therapies for the treatment of neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA, and FAMPYRA for the treatment of multiple sclerosis (MS); FUMADERM for the treatment of plaque psoriasis; and SPINRAZA to treat spinal muscular atrophy. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), and other conditions; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. The company's Phase II clinical trial products comprise Opicinumab for MS; BAN2401 for Alzheimer's disease; BIIB092 for PSP; Natalizumab for Acute Ischemic Stroke and Epilepsy; and BG00011 for idiopathic pulmonary fibrosis. Its Phase I/IIa clinical trial products consist of BIIB080 for patients with mild AD. The company's Phase I clinical trial products comprise Aducanumab for Alzheimer's disease; BIIB076, an anti-tau monoclonal antibody; and BIIB054 for Parkinson's disease. Biogen Inc. offers products through its sales force and marketing groups. It has strategic collaboration with Ionis Pharmaceuticals to develop drug candidates for neurological diseases. The company was formerly known as Biogen Idec Inc. and changed its name to Biogen Inc. in March 2015. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:BIIB
CUSIP09062X10
Phone617-679-2000
Debt
Debt-to-Equity Ratio0.42
Current Ratio3.23
Quick Ratio2.95
Price-To-Earnings
Trailing P/E Ratio16.12
Forward P/E Ratio14.88
P/E Growth1.71
Sales & Book Value
Annual Sales$12.27 billion
Price / Sales6.13
Cash Flow$27.3451 per share
Price / Cash13.04
Book Value$59.56 per share
Price / Book5.99
Profitability
EPS (Most Recent Fiscal Year)$21.81
Net Income$2.54 billion
Net Margins23.54%
Return on Equity37.64%
Return on Assets20.32%
Miscellaneous
Employees7,300
Outstanding Shares211,010,000
Market Cap$74,492.13
Biogen (NASDAQ:BIIB) Frequently Asked Questions
What is Biogen's stock symbol?
Biogen trades on the NASDAQ under the ticker symbol "BIIB."
How were Biogen's earnings last quarter?
Biogen Inc (NASDAQ:BIIB) released its quarterly earnings data on Tuesday, April, 24th. The biotechnology company reported $6.05 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.93 by $0.12. The biotechnology company had revenue of $3.13 billion for the quarter, compared to analyst estimates of $3.15 billion. Biogen had a return on equity of 37.64% and a net margin of 23.54%. The firm's revenue for the quarter was up 11.4% compared to the same quarter last year. During the same period in the previous year, the company posted $5.20 EPS. View Biogen's Earnings History.
When is Biogen's next earnings date?
What price target have analysts set for BIIB?
29 brokerages have issued twelve-month price objectives for Biogen's stock. Their forecasts range from $262.15 to $425.00. On average, they expect Biogen's share price to reach $361.3019 in the next year. This suggests a possible upside of 2.0% from the stock's current price. View Analyst Ratings for Biogen.
What is the consensus analysts' recommendation for Biogen?
29 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biogen in the last year. There are currently 9 hold ratings and 20 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Biogen stock?
Here are some recent quotes from research analysts about Biogen stock:
- 1. HC Wainwright analysts commented, "Valuation and risks. Our PT of $363/share is based on a discounted cash flow analysis using a 10% discount rate and 2.5% growth rate, in line with the expected discount and growth parameters of a commercial multiproduct biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) a smaller than anticipated commercial opportunity due to market size, competition, and/or pricing." (7/9/2018)
- 2. Mizuho analysts commented, "We also note full year 2017 consensus is already above the company’s guidance on both top and bottom lines (guidance last updated in 2Q17) 1. Spinraza. We believe investors will continue to be focused on the performance of the Spinraza launch and information from management on uptake trends. At the recent JPM conference, BIIB commented that for Spinraza they see a benefit from the new launch period in large territories and then a moderate rate of growth, noting that they see reasonable growth in the US in the coming quarters and that a lot of the growth will come outside the US as new countries receive approvals. This was similar to commentary from management in the 3Q17 call. Consensus has 4Q over 3Q growth of 11% and 51% in the US and Ex-US for Spinraza." (1/18/2018)
- 3. Cantor Fitzgerald analysts commented, "MS franchise appears poised for modest negative growth. A tepid patient population growth rate combined with encroaching competition from new agents means existing franchise assets may have achieved peak revenues already, in our opinion." (10/24/2017)
- 4. Citigroup Inc analysts commented, "We're downgrading the stock to neutral from buy as we don't think the street fully appreciates Avexis competition and in coming 6-12 months we think MS pricing concerns in form of greater rebating get louder as we approach Gilenya losing patent and Celgene's Ozanimod launch," (10/23/2017)
- 5. Stifel Nicolaus analysts commented, "gigantic" aducanumab phase 3 trial, which started in 2015 and was 50 percent enrolled in the second quarter of 2017, Shrader commented in his upgrade note. This should be seen as a "no news is good news" scenario as the Data and Safety Monitoring Board has likely seen a lot of data and hasn't reported anything negative.Second, Biogen's partner Eisai is set to report an interim outlook at its plaque-busting mAb that targets the form of Ab plaque thought to lead to neuronal destruction, the analyst continued. The only possible negative outcome would be strong plaque removal with no hints of cognitive benefit and any other result could either be very good or OK.Third, Biogen's often ignored stroke programs address a very large market. Of particular note, the company's Tysabri stoke program uncovered the "same cognitive and energy benefits in stroke patients that are routinely reported in MS patients" and turning this effect into a clinical endpoint that would be acceptable for the U.S. Food and Drug Administration is the likely next step.Finally, Ocrelizumab as part of the company's base business is "meh not mud," the analyst added. The therapy remains a drug with "remarkable anti inflammatory properties," but a commercial rollout will likely be "measured." (10/17/2017)
Who are some of Biogen's key competitors?
Some companies that are related to Biogen include Amgen (AMGN), Gilead Sciences (GILD), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Neurocrine Biosciences (NBIX), bluebird bio (BLUE), Qiagen (QGEN), AveXis (AVXS), BIO-TECHNE (TECH), Ablynx (ABLYF), China Biologic Products (CBPO), Spark Therapeutics (ONCE), argenx (ARGX), Aerie Pharmaceuticals (AERI) and Crispr Therapeutics (CRSP).
Who are Biogen's key executives?
Biogen's management team includes the folowing people:
- Mr. Michel Vounatsos, CEO & Director (Age 56)
- Mr. Jeffrey D. Capello, Exec. VP & CFO (Age 53)
- Mr. Gregory F. Covino, VP of Fin. & Chief Accounting Officer (Age 52)
- Ms. Susan H. Alexander, Exec. VP, Chief of Legal & Corp. Services and Corp. Sec. (Age 61)
- Dr. Michael D. Ehlers, Exec. VP and Head of R&D (Age 49)
Has Biogen been receiving favorable news coverage?
Media stories about BIIB stock have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Biogen earned a news impact score of 0.11 on Accern's scale. They also assigned media coverage about the biotechnology company an impact score of 44.72 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near future.
Who are Biogen's major shareholders?
Biogen's stock is owned by many different of institutional and retail investors. Top institutional investors include Swedbank (0.27%), Assenagon Asset Management S.A. (0.12%), Retirement Systems of Alabama (0.11%), Bank of Montreal Can (0.10%), Manning & Napier Group LLC (0.10%) and Cambiar Investors LLC (0.09%). Company insiders that own Biogen stock include Adriana Karaboutis, Alexander J Denner, Alfred Sandrock, Brian S Posner, Caroline Dorsa, George A Scangos, Michel Vounatsos, Paul J Clancy, Robert W Pangia and Susan H Alexander. View Institutional Ownership Trends for Biogen.
Which major investors are selling Biogen stock?
BIIB stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, NN Investment Partners Holdings N.V., Meag Munich Ergo Kapitalanlagegesellschaft MBH, Gateway Investment Advisers LLC, Cambiar Investors LLC, Montrusco Bolton Investments Inc., Retirement Systems of Alabama and Atria Investments LLC. Company insiders that have sold Biogen company stock in the last year include Alfred Sandrock, Robert W Pangia and Susan H Alexander. View Insider Buying and Selling for Biogen.
Which major investors are buying Biogen stock?
BIIB stock was acquired by a variety of institutional investors in the last quarter, including Swedbank, Assenagon Asset Management S.A., Bank of Montreal Can, Cullinan Associates Inc., DnB Asset Management AS, Bedrijfstakpensioenfonds Voor DE Media PNO, State of Alaska Department of Revenue and Fisher Asset Management LLC. Company insiders that have bought Biogen stock in the last two years include Alexander J Denner and Michel Vounatsos. View Insider Buying and Selling for Biogen.
How do I buy shares of Biogen?
Shares of BIIB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Biogen's stock price today?
One share of BIIB stock can currently be purchased for approximately $354.31.
How big of a company is Biogen?
Biogen has a market capitalization of $74.49 billion and generates $12.27 billion in revenue each year. The biotechnology company earns $2.54 billion in net income (profit) each year or $21.81 on an earnings per share basis. Biogen employs 7,300 workers across the globe.
How can I contact Biogen?
Biogen's mailing address is 225 BINNEY STREET, CAMBRIDGE MA, 02142. The biotechnology company can be reached via phone at 617-679-2000.
MarketBeat Community Rating for Biogen (NASDAQ BIIB)
MarketBeat's community ratings are surveys of what our community members think about Biogen and other stocks. Vote "Outperform" if you believe BIIB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIIB will underperform the S&P 500 over the long term. You may vote once every thirty days.
